



## Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

September 22, 2025

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Sep. 22, 2025-- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology, will present data evaluating the safety, tolerability, and efficacy of sequencing systemic ipilimumab and nivolumab with Delcath's CHEMOSAT<sup>®</sup> Hepatic Delivery System for percutaneous hepatic perfusion with melphalan in patients with metastatic uveal melanoma.

**Title:** Combined Percutaneous Hepatic Perfusion with Ipilimumab plus Nivolumab in Metastatic Uveal Melanoma: a single center, open-label, randomized, phase 2 study (CHOPIN)

**Session Title:** [Melanoma and other skin tumours](#)

**Session Date and Time:** Saturday, October 18, 2025 3:20 p.m. CET / 9:20 a.m. EST

**Abstract Number:** LBA59

**Presenter:** Ellen Kapiteijn, MD

The poster will be available at <https://delcath.com/investors/events-presentations/> when the ESMO embargo is released on October 18, 2025.

### About Delcath Systems, Inc., HEPZATO KIT, and CHEMOSAT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT<sup>™</sup> (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT<sup>®</sup> Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtering hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full [Prescribing Information](#), including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

### Forward-Looking Statements

This release contains forward-looking statements, including statements regarding the expected release of clinical trial results, which are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, delays in the presentation of the data, or other unforeseen issues relating to the release of the clinical trial results. For a detailed discussion of these and other risks, please refer to Delcath's filings with the SEC.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250922014721/en/): <https://www.businesswire.com/news/home/20250922014721/en/>

**Investor Relations Contact:**

ICR Healthcare

[investorrelations@delcath.com](mailto:investorrelations@delcath.com)

Source: Delcath Systems, Inc.